Tiletamine Hcl; Zolazapam Hcl

Verify with FDA CVM →

523 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
523
Total Reports
115
Deaths Reported
2200.0%
Death Rate

Active Ingredients

Tiletamine Hcl; Zolazapam Hcl

Administration Routes

IntramuscularUnknownIntravenousSubcutaneousOtherOphthalmic

Species Affected

Dog 246
Cat 226
Unknown 33
Human 8
Pig 4
White tailed deer 2
Primate 2
Bear 1
Moose 1

Most Affected Breeds

Domestic Shorthair 112
Dog (unknown) 77
Unknown 45
Cat (unknown) 44
Cat (other) 29
Retriever - Labrador 23
Domestic Longhair 19
Shih Tzu 8
Boxer (German Boxer) 8
Domestic Mediumhair 7

Most Reported Reactions

INEFFECTIVE, ANESTHESIA 94
Death 67
Lack of efficacy - NOS 54
Cardiac arrest 41
INEFFECTIVE, SEDATION 35
Incorrect route of drug administration 35
Underdose 34
Lethargy (see also Central nervous system depression in 'Neurological') 32
Recovery prolonged 31
Vomiting 29
Death by euthanasia 27
Behavioural disorder NOS 27

Outcome Breakdown

Recovered/Normal
213 (42.4%)
Ongoing
109 (21.7%)
Died
70 (13.9%)
Outcome Unknown
64 (12.7%)
Euthanized
45 (9.0%)
Recovered with Sequela
1 (0.2%)

Data Summary

Metric Value
Total adverse event reports 523
Reports involving death 115
Case-fatality rate (reported events) 2200.0%
Distinct species in reports 9
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Tiletamine Hcl; Zolazapam Hcl Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 523 adverse event reports referencing Tiletamine Hcl; Zolazapam Hcl, including 115 reports in which the animal died — a 2200.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Tiletamine Hcl; Zolazapam Hcl. Reported administration routes include Intramuscular, Unknown, Intravenous, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Tiletamine Hcl; Zolazapam Hcl reports are Dog (246 reports), Cat (226 reports), Unknown (33 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (112), Dog (unknown) (77), Unknown (45) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Tiletamine Hcl; Zolazapam Hcl are INEFFECTIVE, ANESTHESIA (94), Death (67), Lack of efficacy - NOS (54), Cardiac arrest (41). Of the 502 reports with a coded outcome, Recovered/Normal is the leading category at 42.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Tiletamine Hcl; Zolazapam Hcl.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial